AMPH vs HIK.L
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets.
Side-by-side fundamentals
| Metric | AMPH | HIK.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $20.24 | £15.73 | |
| Market cap as of 2026-08-06 | $892M | n/a | |
| P/E as of 2026-08-06 | 11.07 | n/a | |
| PEG as of 2026-08-06 | -1.94 | n/a | |
| Net margin as of 2026-08-06 | +11.0% | n/a | |
| Gross margin as of 2026-08-06 | +47.3% | n/a | |
| Operating margin as of 2026-08-06 | +16.2% | n/a | |
| ROE as of 2026-08-06 | +10.2% | n/a | |
| ROA as of 2026-08-06 | +4.8% | n/a | |
| Debt / equity as of 2026-08-06 | 0.79 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | -1.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +13.0% | n/a | |
| Beta as of 2026-08-06 | 0.91 | n/a | |
| 1-year return as of 2026-08-05 close | -5.6% | -18.9% | AMPH higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.